<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440257</url>
  </required_header>
  <id_info>
    <org_study_id>CL007_140</org_study_id>
    <nct_id>NCT01440257</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemoCentryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChemoCentryx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of treatment with CCX140-B on urinary
      albumin excretion in subjects with type 2 diabetes mellitus and albuminuria, as well as to
      study the safety and efficacy of the medication in this patient population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 24-hour urinary albumin excretion</measure>
    <time_frame>84 days</time_frame>
    <description>The primary efficacy objective of this study is to evaluate the effect of CCX140-B treatment on urinary albumin excretion by measuring change from baseline in 24-hour urinary albumin excretion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of adverse events</measure>
    <time_frame>84 days</time_frame>
    <description>The primary safety objective of this study is to evaluate the safety and tolerability of CCX140-B in subjects with type 2 diabetes mellitus (T2DM) with albuminuria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin A1c</measure>
    <time_frame>84 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo (Group A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active study medication (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCX140-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules once daily</description>
    <arm_group_label>Placebo (Group A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX140-B</intervention_name>
    <description>CCX140-B capsules once daily (Group B)</description>
    <arm_group_label>Active study medication (Group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Aged 18-75 years inclusive, with documented previously diagnosed type 2 diabetes
             mellitus (per American Diabetes Association [ADA] criteria), and treated with oral
             antidiabetic drugs

          -  Albumin:creatinine ratio (ACR) of 200 to 3000 mg/g creatinine, inclusive, based on two
             values obtained from two first morning urine samples taken on two separate days during
             the screening period

          -  Estimated glomerular filtration rate based on serum creatinine (eGFR, determined by
             Modification of Diet in Renal Disease [MDRD] equation) of â‰¥ 25 mL/min/1.73 m(2)

          -  Must be on a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an
             angiotensin receptor blocker (ARB) for at least 8 weeks prior to screening

          -  Fasting plasma glucose less than 270 mg/dL at screening

        Key Exclusion Criteria:

          -  Type 1 diabetes mellitus or history of diabetic ketoacidosis

          -  Previous renal transplant or known non-diabetic renal disease, except related to
             hypertension

          -  Undergone renal dialysis at any time in the past

          -  Received chronic (more than 7 days continuously) systemic glucocorticoid or other
             immunosuppressive treatment within 8 weeks of screening

          -  Use of bardoxolone, atrasentan or other endothelin antagonist within 8 weeks of
             screening

          -  Received chronic (more than 7 days continuously) non-steroidal anti-inflammatory drug
             (NSAID) treatment within 2 weeks of screening

          -  Cardiac failure (class III or IV), history of unstable angina, symptomatic coronary
             artery disease, myocardial infarction or stroke within 12 weeks of screening

          -  Poorly-controlled blood pressure (systolic blood pressure &gt;155 or diastolic blood
             pressure &gt;95, with blood pressure measured in the seated position after at least 5
             minutes of rest)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirow Bekker, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ChemoCentryx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>January 8, 2015</last_update_submitted>
  <last_update_submitted_qc>January 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

